{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:21:01Z","timestamp":1773296461591,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.clml.2012.09.011","type":"journal-article","created":{"date-parts":[[2012,10,23]],"date-time":"2012-10-23T22:46:10Z","timestamp":1351032370000},"page":"55-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and Efficacy of Triplet Regimens in Newly Diagnosed Light Chain Amyloidosis"],"prefix":"10.1016","volume":"13","author":[{"given":"Ajai","family":"Chari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Barley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keren","family":"Osman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.09.011_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.09.011_bib2","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.09.011_bib3","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1182\/blood-2004-08-3231","article-title":"The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)","volume":"105","author":"Palladini","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib5","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.11325","article-title":"Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone","volume":"92","author":"Kastritis","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2012.09.011_bib6","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/bmt.2010.234","article-title":"Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006","volume":"46","author":"Gertz","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2012.09.011_bib7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00277-011-1244-x","article-title":"Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide","volume":"91","author":"Palladini","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2012.09.011_bib9","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1182\/blood-2010-07-294405","article-title":"Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1\/2 dose-escalation study","volume":"116","author":"Moreau","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib10","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1182\/blood-2010-07-295485","article-title":"Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis","volume":"116","author":"Sanchorawala","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.09.011_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00277-010-1062-6","article-title":"Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis","volume":"90","author":"Lamm","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2012.09.011_bib13","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib14","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib15","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2012.09.011_bib16","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib17","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2012.09.011_bib18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib19","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2012.09.011_bib20","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.09.011_bib21","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.09.011_bib22","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib23","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/leu.2010.116","article-title":"Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study","volume":"24","author":"Kumar","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2012.09.011_bib24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.09.011_bib25","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2012.09.011_bib26","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA \u2014 Italian multiple myeloma network","volume":"25","author":"Palumbo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.09.011_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.V116.21.622.622","article-title":"A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients >= 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens","volume":"116","author":"Palumbo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib28","first-page":"376","article-title":"Carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma: initial results of phase I\/II MMRC trial","volume":"116","author":"Jakubowiak","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib29","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib30","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CYBORD) produces rapid and complete hematological response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2012.09.011_bib32","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","article-title":"International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation","volume":"117","author":"Cavo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","article-title":"Treatment of multiple myeloma","volume":"8","author":"Rajkumar","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2012.09.011_bib34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1529-8027.2008.00193.x","article-title":"Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy","volume":"13","author":"Chaudhry","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.clml.2012.09.011_bib35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2012.09.011_bib36","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib37","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood.V114.22.3887.3887","article-title":"The weekly infusion of bortezomib reduces peripheral neuropathy","volume":"114","author":"Gay","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.011_bib38","first-page":"2949","article-title":"A 28 day schedule for lenalidomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma","volume":"118","author":"Chari","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2012.09.011_bib39","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12630-010-9288-2","article-title":"Ventricular tachycardia after ondansetron administration in a child with undiagnosed long QT syndrome","volume":"57","author":"McKechnie","year":"2010","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.clml.2012.09.011_bib40","first-page":"172","article-title":"Intravenous ondansetron causing severe bradycardia: two cases","volume":"12","author":"Afonso","year":"2009","journal-title":"Ann Card Anaesth"},{"key":"10.1016\/j.clml.2012.09.011_bib41","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/00000542-200506000-00006","article-title":"Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron","volume":"102","author":"Charbit","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1016\/j.clml.2012.09.011_bib42","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/ALN.0b013e31817fd8c8","article-title":"Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study","volume":"109","author":"Charbit","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.clml.2012.09.011_bib43","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jclinane.2007.03.012","article-title":"Dolasetron-induced torsades de pointes","volume":"19","author":"Turner","year":"2007","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.clml.2012.09.011_bib44","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/BF00689445","article-title":"Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy","volume":"35","author":"Watanabe","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2012.09.011_bib45","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/gfq482","article-title":"Kidney dysfunction during lenalidomide treatment for AL amyloidosis","volume":"26","author":"Specter","year":"2011","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012001760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012001760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:15Z","timestamp":1761870255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012001760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S2152265012001760"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.09.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Triplet Regimens in Newly Diagnosed Light Chain Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}